Detection of complexes between prostate-specific antigen and protease inhibitors in plasma

Clinical Chemistry

Volumn 56, Issue 12, 2010, Pages 1895-1896

  Stenman, Ulf Håkan ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; PROSTATE SPECIFIC ANTIGEN; PROTEINASE INHIBITOR;

ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN DETECTION; CANCER DIAGNOSIS; HUMAN; NOTE; PLASMA; PROSTATE CANCER;

ALPHA 1-ANTICHYMOTRYPSIN; HUMANS; MALE; PLASMA; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 78649846328     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.146159     Document Type: Note

References (6)

1. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lovgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 1991;37:1618-25. (Pubitemid 21905228)
2. Zhu L, Leinonen J, Zhang WM, Finne P, Stenman UH. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1- antichymotrypsin complex together with free or total PSA. Clin Chem 2003; 49:97-103.
3. Stenman UH. Editorial comment on: Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Eur Urol 2007;52:1074-5.
4. Finne P, Auvinen A, Aro J, Juusela H, Määttänen L, Rannikko S, et al. Estimation of prostate cancer risk on the basis of total and free prostatespecific antigen, prostate volume and digital rectal examination. Eur Urol 2002;41:619-27.
5. Finne P, Auvinen A, Maattanen L, Tammela TL, Ruutu M, Juusela H, et al. Diagnostic value of free prostate-specific antigen among men with a prostatespecific antigen level of <3.0 microg per liter. Eur Urol 2008;54:362-70. (Pubitemid 351885247)
6. Southwick PC, Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, et al. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial. J Urol 1999;162:1346-51.